伴t(8;21)的急性髓系白血病对阿伐替尼的快速反应及异基因造血干细胞移植后复发伴突变 - Suppr

Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and mutation relapse post allo-HSCT.

作者信息

Xue Song, Huang Wenqiu, Liu Fuhong, Zhang Yongping, Hao Qi, Cui Bin, Chen Suning, Wang Jingbo

机构信息

Department of Hematology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.

Department of Radiology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.

出版信息

Leuk Lymphoma. 2022 Sep;63(9):2247-2250. doi: 10.1080/10428194.2022.2064994. Epub 2022 Apr 19.

DOI:10.1080/10428194.2022.2064994

PMID:35440293

Abstract

摘要

相似文献

Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and mutation relapse post allo-HSCT.伴t(8;21)的急性髓系白血病对阿伐替尼的快速反应及异基因造血干细胞移植后复发伴突变

Leuk Lymphoma. 2022 Sep;63(9):2247-2250. doi: 10.1080/10428194.2022.2064994. Epub 2022 Apr 19.

Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.伴 t(8;21)和 KIT 突变的儿童急性髓系白血病患者在干细胞移植后应用 avapritinib 治疗：四例报告。

Ann Hematol. 2024 Sep;103(9):3795-3800. doi: 10.1007/s00277-024-05810-z. Epub 2024 May 28.

[The efficacy and safety of avapritinib in the treatment of molecular biologically positive core binding factor-acute myeloid leukemia with KIT mutation after allogeneic hematopoietic stem cell transplantation].阿伐替尼治疗异基因造血干细胞移植后分子生物学阳性且伴有KIT突变的核心结合因子急性髓系白血病的疗效与安全性

Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):761-766. doi: 10.3760/cma.j.cn121090-20240129-00043.

[Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review].[两例异基因造血干细胞移植后序贯阿伐替尼治疗的RUNX1-RUNX1T1阳性急性髓系白血病合并系统性肥大细胞增多症病例及文献复习]

Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):505-508. doi: 10.3760/cma.j.cn121090-20240313-00092.

Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation.阿伐替尼对经过大量治疗的伴有t(8;21)和KIT突变的急性髓系白血病有快速且深度的反应。

Ann Hematol. 2022 Oct;101(10):2347-2350. doi: 10.1007/s00277-022-04897-6. Epub 2022 Jun 29.

KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine.用阿伐普替尼和地西他滨治疗的KIT突变型儿童核心结合因子系统性肥大细胞增多症-急性髓系白血病

Pediatr Blood Cancer. 2024 Apr;71(4):e30898. doi: 10.1002/pbc.30898. Epub 2024 Jan 30.

Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.异基因造血干细胞移植可改善基于 MRD 指导治疗的高危儿童 t（8；21）急性髓系白血病首次缓解期的预后。

BMC Cancer. 2020 Jun 15;20(1):553. doi: 10.1186/s12885-020-07043-5.

The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.无 FLT3-ITD、NPM1 和双等位 CEBPA 突变的中危急性髓系白血病微小残留病检测对预后和缓解后治疗选择的影响。

Hematology. 2021 Dec;26(1):179-185. doi: 10.1080/16078454.2021.1880753.

Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.KIT 和 FLT3-ITD 突变状态与微小残留病灶水平的联合检测可指导伴有 inv(16) 的初诊完全缓解成人急性髓系白血病患者的治疗策略。

Hematol Oncol. 2022 Oct;40(4):724-733. doi: 10.1002/hon.3015. Epub 2022 May 15.

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.诊断时WT1转录水平低预示着接受化疗或异基因造血干细胞移植的t(8;21)急性髓系白血病患者预后不良。

Chin J Cancer. 2016 May 19;35:46. doi: 10.1186/s40880-016-0110-6.

引用本文的文献

Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression.抗CD19嵌合抗原受体T细胞疗法治疗复发/难治性伴有异常CD19表达的t(8;21)急性髓系白血病

Front Immunol. 2025 Jul 21;16:1617589. doi: 10.3389/fimmu.2025.1617589. eCollection 2025.

[Avapritinib for systemic mastocytosis with an associated myelodysplastic/myeloproliferative neoplasm: a case report and literature review].[阿伐普替尼治疗伴有骨髓增生异常/骨髓增殖性肿瘤的系统性肥大细胞增多症：一例报告及文献综述]

Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):468-472. doi: 10.3760/cma.j.cn121090-20241011-00389.

Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review.阿伐替尼单药治疗可使经过大量治疗的KIT D816H突变的t(8;21)急性髓系白血病迅速且深度缓解：一例报告及文献综述

Ann Hematol. 2025 Jul;104(7):3889-3892. doi: 10.1007/s00277-025-06388-w. Epub 2025 Jun 27.

Case Report: Rapid response to gemtuzumab-ozogamicin in a pediatric patient with refractory systemic mastocytosis with AML1::ETO+ acute myeloid leukemia.病例报告：一名患有难治性系统性肥大细胞增多症合并AML1::ETO+急性髓系白血病的儿科患者对吉妥珠单抗-奥佐米星迅速产生反应。

Front Immunol. 2025 Apr 9;16:1566805. doi: 10.3389/fimmu.2025.1566805. eCollection 2025.

Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):761-766. doi: 10.3760/cma.j.cn121090-20240129-00043.

Ann Hematol. 2024 Sep;103(9):3795-3800. doi: 10.1007/s00277-024-05810-z. Epub 2024 May 28.

Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.基因组测序整合驱动 PDGFRA 治疗靶点在 T 细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤中的应用。

Clin Cancer Res. 2023 Nov 14;29(22):4613-4626. doi: 10.1158/1078-0432.CCR-22-2562.

Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation.阿伐普替尼对异基因造血干细胞移植后接受免疫治疗失败的伴有t(8;21)和试剂盒突变的急性髓系白血病微小残留病有效。

Bone Marrow Transplant. 2023 Jul;58(7):777-783. doi: 10.1038/s41409-023-01973-x. Epub 2023 Apr 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and mutation relapse post allo-HSCT.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献